Abstract
Despite negative topline phase 3 clinical trial results for bapineuzumab and solanezumab in mild to moderate AD, findings from these trials and recent advances suggest renewed optimism for anti-amyloid therapies. Aβ immunotherapy has now demonstrated its ability to engage CNS Aβ and modify downstream CNS biomarkers in bapineuzumab treated patients, and to show likely cognitive benefits in mild patients treated with solanezumab. The current availability of potent BACE inhibitors provides additional opportunities to test the value of reducing Aβ in the clinic. Trial enhancements, such as selecting and enriching for early stage AD, treating participants longer and using more sensitive composite endpoints may further improve our chances of demonstrating clinical efficacy and securing beneficial treatments for patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Salloway S, Sperling R, Honig L, et al. A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with mild to moderate Alzheimer’s disease who are apolipoprotein E e4 non-carriers (presented at the 16th congress of the European Federation of Neurological Societies, Stockholm, Sweden, September 11, 2012). European Journal of Neurology 2012: 19(Suppl. 1), 70.
Sperling R, Salloway S, Raskind M, et al. A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with mild to moderate Alzheimer’s disease who are apolipoprotein E e4 carriers (presented at the 16th Congress of the European Federation of Neurological Societies, Stockholm. Sweden, September 11, 2012). European Journal of Neurology 2012: 19(Suppl. 1), 70.
Doody, RS. Results of Immune-Based Trials in Neurological Disorders. Presented at the 2012 Annual Meeting of the American Neurological Association, Boston, Massachusetts, October 8, 2012.
Yang L, Rieves D, Ganley C. Brain amyloid imaging—FDA approval of florbetapir F18 injection. N Engl J Med. 2012; 367:885–887
Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012; 367:795–804.
Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature. 2012; 488:96–99.
Doraiswamy PM, Sperling RA, Coleman RE, et al. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: A multicenter study. Neurology. 2012 Aug 1. [Epub ahead of print] PubMed PMID: 22786606.
Samtani MN, Raghavan N, Shi Y, Novak G, Faraum M, Lobanov V, Schultz T, Yang E, Diberaardo A, Narayan VA; & the Alzheimer’s Disease Neuroimaging Initiative. Disease Progression Model in MCI Subjects from Alzheimer’s Disease Neuroimaging Initiative: CSF Biomarkers Predict Population Subtypes. Br J Clin Pharmacol. 2012 Apr 26. doi: 10.111365-2125.2012.04308.x. [Epub ahead of print] PubMed PMID 22534009.
Cedarbaum JM, Jaros M, Hernandez C, et al. Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer’s disease clinical trials. Alzheimers Dement. 2012 May 31. [Epub ahead of print] PubMed PMID: 22658286.
Raghavan N, Samtani MN, Faraum M, et al. The ADAS-COG Revisited: Novel Composite Scales Based on ADAS-Cog To Improve Efficiency in MCI and Early AD Trials. Alzheimers Dement. 2012 In press.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grundman, M., Dibernardo, A., Raghavan, N. et al. 2012: A watershed year for Alzheimer’s disease research. J Nutr Health Aging 17, 51–53 (2013). https://doi.org/10.1007/s12603-013-0002-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12603-013-0002-2